Imvax Heads to FDA With 6-Month Survival Gain in Glioblastoma, Despite Endpoint Miss

While Imvax’s autologous immunotherapy IGV-001 missed the primary endpoint of progression-free survival in a Phase IIb trial, the company will request a meeting with the FDA to discuss next steps for “synergistic” treatment.